• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A cloudy story: Guillain–Barré syndrome concealed by a spontaneous intracerebral haemorrhage
We present a case of Guillain–Barré syndrome (GBS), probably associated with influenza vaccine, occurring in a patient some days after a spontaneous haemorrhagic stroke. A 79-year-old woman was admitted to the neurosurgery department after a sudden severe headache, dizziness, and progressive generalised weakness. She had a history of hypertension and paroxysmal atrial fibrillation in dicumarolic therapy. Head CT scan showed a haemorrhagic stroke in left cerebellum, with compression on the fourth ventricle.
Source: Clinical Neurophysiology - October 22, 2012 Category: Neuroscience Authors: V. Mantero, L. De Toni Franceschini, L. Abate, F. Villa, A. Patruno, S. Jann, G. Citerio Tags: Letters to the Editor Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news